Literature DB >> 20065181

Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.

Inga S Grills1, Victor S Mangona, Robert Welsh, Gary Chmielewski, Erika McInerney, Shannon Martin, Jennifer Wloch, Hong Ye, Larry L Kestin.   

Abstract

PURPOSE To compare outcomes between lung stereotactic radiotherapy (SBRT) and wedge resection for stage I non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS One hundred twenty-four patients with T1-2N0 NSCLC underwent wedge resection (n = 69) or image-guided lung SBRT (n = 58) from February 2003 through August 2008. All were ineligible for anatomic lobectomy; of those receiving SBRT, 95% were medically inoperable, with 5% refusing surgery. Mean forced expiratory volume in 1 second and diffusing capacity of lung for carbon monoxide were 1.39 L and 12.0 mL/min/mmHg for wedge versus 1.31 L and 10.14 mL/min/mmHg for SBRT (P = not significant). Mean Charlson comorbidity index and median age were 3 and 74 years for wedge versus 4 and 78 years for SBRT (P < .01, P = .04). SBRT was volumetrically prescribed as 48 (T1) or 60 (T2) Gy in four to five fractions. Results Median potential follow-up is 2.5 years. At 30 months, no significant differences were identified in regional recurrence (RR), locoregional recurrence (LRR), distant metastasis (DM), or freedom from any failure (FFF) between the two groups (P > .16). SBRT reduced the risk of local recurrence (LR), 4% versus 20% for wedge (P = .07). Overall survival (OS) was higher with wedge but cause-specific survival (CSS) was identical. Results excluding synchronous primaries, nonbiopsied tumors, or pathologic T4 disease (wedge satellite lesion) showed reduced LR (5% v 24%, P = .05), RR (0% v 18%, P = .07), and LRR (5% v 29%, P = .03) with SBRT. There were no differences in DM, FFF, or CSS, but OS was higher with wedge. CONCLUSION Both lung SBRT and wedge resection are reasonable treatment options for stage I NSCLC patients ineligible for anatomic lobectomy. SBRT reduced LR, RR, and LRR. In this nonrandomized population of patients selected for surgery versus SBRT (medically inoperable) at physician discretion, OS was higher in surgical patients. SBRT and surgery, however, had identical CSS.

Entities:  

Mesh:

Year:  2010        PMID: 20065181     DOI: 10.1200/JCO.2009.25.0928

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  133 in total

1.  What is the current status of Stereotactic body radiotherapy for stage I non-small cell lung cancer?

Authors:  Matthias Guckenberger
Journal:  J Thorac Dis       Date:  2011-09       Impact factor: 2.895

2.  [Image-guided radiation therapy].

Authors:  J Boda-Heggemann; M Guckenberger; U Ganswindt; C Belka; H Wertz; M Blessing; F Wenz; M Fuss; F Lohr
Journal:  Radiologe       Date:  2012-03       Impact factor: 0.635

3.  Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.

Authors:  Charles B Simone; Jay F Dorsey
Journal:  Ann Transl Med       Date:  2015-08

4.  PET-CT limitations in early stage non-small cell lung cancer: to whom more aggressive approach in radiotherapy and surgery should be directed?

Authors:  Lucyna Kepka; Joanna Socha
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

5.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

6.  Triaging early-stage lung cancer patients into non-surgical pathways: who, when, and what?

Authors:  Rameses Sroufe; Feng-Ming Spring Kong
Journal:  Transl Lung Cancer Res       Date:  2015-08

7.  Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer.

Authors:  Jacob Y Shin; Ja Kyoung Yoon; Gaurav Marwaha
Journal:  Lung       Date:  2018-03-17       Impact factor: 2.584

Review 8.  Proton Therapy in Non-small Cell Lung Cancer.

Authors:  Shane Mesko; Daniel Gomez
Journal:  Curr Treat Options Oncol       Date:  2018-11-27

9.  A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer.

Authors:  Christopher Cao; Daniel Wang; Caroline Chung; David Tian; Andreas Rimner; James Huang; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2018-09-15       Impact factor: 5.209

10.  Radiotherapy for a second primary lung cancer arising post-pneumonectomy: planning considerations and clinical outcomes.

Authors:  Sashendra Senthi; Cornelis J A Haasbeek; Frank J Lagerwaard; Wilko F Verbakel; Patricia F de Haan; Ben J Slotman; Suresh Senan
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.